11
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
12
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
13
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
14
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
15
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
Suche einschränken
&# 8364
150
>
150
> expanding
150
Biotechnology
150
Cancer
150
Computational Biology
150
Ecology
150
Infectious Diseases
150
Plant Biology
150
Science Policy
150
already approved immuno
150
assumed lower r
150
based prices
150
based pricing
150
based pricing model
150
based pricing models
150
consistently lower
150
cumulative indication
150
daratumumab &# 8217
150
daratumumab </ p
150
daratumumab per vial
150
deterministic stepwise analysis
150
dutch list prices
150
eligible patient population
150
indication (&# 8364
150
indication broadening
150
indication expansion
150
indications due
150
initial r
150
initial years
150
l &# 246
150
larger patient populations
150
lower estimates resulted
150
model proposed
150
modeled cbps depending
150
ongoing discussions
150
pembrolizumab (&# 8364
150
pembrolizumab per vial
150
pharmaceutical pricing
150
potential effect
150
profit margin
150
profit margin contributed
150
registered indications
150
scenario analysis
150
sensitivity analysis showed
150
significant impact
150
significant influence
150
smaller patient populations
150
study focuses
150
xlink \
150